Genetics, Pediatric Epilepsy
A round-up of the top epilepsy research news from the past month.
RogCon and The Florey Institute of Neuroscience presented preclinical data on the company's lead program, RC-222, an antisense oligonucleotide designed to down-regulate SCN2A.
Pediatric Epilepsy
A retrospective study evaluating continuous electroencephalography (cEEG) of children in intensive care units (ICUs) found a higher than anticipated number of seizures.
Three FDA-approved drugs designed to treat other conditions significantly reduced seizure-like movement in zebrafish.
Discover the latest about what's happening at CURE and in our community in the December 2018 CURE Update from Chief Scientific Officer, Laura Lubbers!
Pediatric Epilepsy
Study finds the Refractory Epilepsy Screening Tool for LGS may be a valuable clinical tool in identifying patients requiring further diagnostic evaluation for LGS.
Genetics
Results from a genome-wide mega-analysis show an enrichment for monogenic epilepsy genes as well as known targets of antiepileptic drugs. Using SNP-based heritability analyses, researchers disentangle both the unique and overlapping genetic basis to seven different epilepsy subtypes.
A history of intolerable adverse drug reactions has a large impact on the tolerability of future antiepilepsy drug regimens.
Genetics, Pediatric Epilepsy
Research finds when a "poison" exon on the SCN1A gene is incorporated, it prematurely cancels the production of a crucial protein, which disrupts neural function leading to seizure disorders.
